CD44 and glioma: In addition, we explored the CGGA, an independent glioma database, and validated expressions of the CCNB1/CDC42/MAPK7/CD44 gene signatures in WHO grade II, III, and IV GBM tumors using the Analysis of variance (ANOVA) (Figure 5I–L), with p < 0.05 considered statistically significant.